Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 400

1.

Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients.

Tricot G, Jagannath S, Vesole D, Nelson J, Tindle S, Miller L, Cheson B, Crowley J, Barlogie B.

Blood. 1995 Jan 15;85(2):588-96. Review.

3.
5.

Transplantation of enriched and purged peripheral blood progenitor cells from a single apheresis product in patients with non-Hodgkin's lymphoma.

Negrin RS, Kusnierz-Glaz CR, Still BJ, Schriber JR, Chao NJ, Long GD, Hoyle C, Hu WW, Horning SJ, Brown BW, et al.

Blood. 1995 Jun 1;85(11):3334-41.

6.

Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of multiple myeloma patients: positive selection and transplantation of enriched CD34+ cells to remove circulating tumor cells.

Lemoli RM, Fortuna A, Motta MR, Rizzi S, Giudice V, Nannetti A, Martinelli G, Cavo M, Amabile M, Mangianti S, Fogli M, Conte R, Tura S.

Blood. 1996 Feb 15;87(4):1625-34.

7.

Collection, tumor contamination, and engraftment kinetics of highly purified hematopoietic progenitor cells to support high dose therapy in multiple myeloma.

Tricot G, Gazitt Y, Leemhuis T, Jagannath S, Desikan KR, Siegel D, Fassas A, Tindle S, Nelson J, Juttner C, Tsukamoto A, Hallagan J, Atkinson K, Reading C, Hoffman R, Barlogie B.

Blood. 1998 Jun 15;91(12):4489-95.

8.

Transplantation of CD34+ peripheral blood progenitor cells after high-dose chemotherapy for patients with advanced multiple myeloma.

Schiller G, Vescio R, Freytes C, Spitzer G, Sahebi F, Lee M, Wu CH, Cao J, Lee JC, Hong CH, et al.

Blood. 1995 Jul 1;86(1):390-7.

9.

Successful mobilization of peripheral blood stem cells in heavily pretreated myeloma patients with G-CSF alone.

Kröger N, Zeller W, Hassan HT, Krüger W, Renges H, Hummel K, Gutensohn K, Lölliger C, Zander AR.

Ann Hematol. 1998 Jun;76(6):257-62.

PMID:
9692813
10.

Factors affecting hemopoietic recovery after high-dose therapy and autologous peripheral blood progenitor cell transplantation: a single center experience.

Olivieri A, Offidani M, Montanari M, Ciniero L, Cantori I, Ombrosi L, Masia CM, Centurioni R, Mancini S, Brunori M, Leoni P.

Haematologica. 1998 Apr;83(4):329-37.

11.

Role of CD34+ cells in engraftment after high-dose melphalan in multiple myeloma patients given peripheral blood stem cell rescue.

Millar BC, Millar JL, Bell JB, Raje N, Milan S, Mehta J, Singhal S, Middleton GW, Sheperd V, Catovsky D, Powles RL.

Bone Marrow Transplant. 1996 Nov;18(5):871-8.

PMID:
8932839
12.

Preceding chemotherapy, tumour load and age influence engraftment in multiple myeloma patients mobilized with granulocyte colony-stimulating factor alone.

Desikan KR, Tricot G, Munshi NC, Anaissie E, Spoon D, Fassas A, Toor A, Zangari M, Badros A, Morris C, Vesole DH, Siegel D, Jagannath S, Barlogie B.

Br J Haematol. 2001 Jan;112(1):242-7.

PMID:
11167811
13.

Low-risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support.

Jagannath S, Vesole DH, Glenn L, Crowley J, Barlogie B.

Blood. 1992 Oct 1;80(7):1666-72.

14.

Thiotepa cyclophosphamide followed by granulocyte colony-stimulating factor mobilized allogeneic peripheral blood cells in adults with advanced leukemia.

Bacigalupo A, Van Lint MT, Valbonesi M, Lercari G, Carlier P, Lamparelli T, Gualandi F, Occhini D, Bregante S, Valeriani A, Piaggio G, Pitto A, Benvenuto F, Figari O, De Stefano G, Caimo A, Sessarego M.

Blood. 1996 Jul 1;88(1):353-7.

15.

Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study.

de la Rubia J, Bladé J, Lahuerta JJ, Ribera JM, Martínez R, Alegre A, García-Laraña J, Fernández P, Sureda A, de Arriba F, Carrera D, Besalduch J, García Boyero R, Palomera Bernal L, Hernández MT, García PR, Pérez-Calvo J, Alcalá A, Casado LF, San Miguel J.

Haematologica. 2006 May;91(5):621-7. Epub 2006 Apr 19.

17.

Expression of adhesion molecules on CD34+ cells: CD34+ L-selectin+ cells predict a rapid platelet recovery after peripheral blood stem cell transplantation.

Dercksen MW, Gerritsen WR, Rodenhuis S, Dirkson MK, Slaper-Cortenbach IC, Schaasberg WP, Pinedo HM, von dem Borne AE, van der Schoot CE.

Blood. 1995 Jun 1;85(11):3313-9.

19.

Engraftment with peripheral blood stem cells using noncontrolled-rate cryopreservation: comparison with autologous bone marrow transplantation.

Rosenfeld CS, Gremba C, Shadduck RK, Zeigler ZR, Nemunaitis J.

Exp Hematol. 1994 Mar;22(3):290-4.

PMID:
7509292
20.

Transplantation with selected autologous peripheral blood CD34+Thy1+ hematopoietic stem cells (HSCs) in multiple myeloma: impact of HSC dose on engraftment, safety, and immune reconstitution.

Michallet M, Philip T, Philip I, Godinot H, Sebban C, Salles G, Thiebaut A, Biron P, Lopez F, Mazars P, Roubi N, Leemhuis T, Hanania E, Reading C, Fine G, Atkinson K, Juttner C, Coiffier B, Fière D, Archimbaud E.

Exp Hematol. 2000 Jul;28(7):858-70.

PMID:
10907648

Supplemental Content

Support Center